{"transactions":[{"id":4632515,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:02:18.000Z","date":"2026-09-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":520,"price":23.67,"value":12308.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on September 25, 2025."}],"balance_after":58024,"source":{"system":"sec-edgar","filing":"0001791187-26-000010","document":"form4-10022026_091013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000179118726000010/form4-10022026_091013.xml","form_type":"4"}},{"id":3531960,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-08T20:45:09.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":24250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/8th of the shares subject to the option vest on September 3, 2026 with the remaining shares subject to the option vesting in the following 42 equal monthly installments beginning on October 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":24250,"derivative":{"exercise_price":29.92,"expiration_date":"2036-09-02","underlying":"Common Stock","underlying_shares":24250},"source":{"system":"sec-edgar","filing":"0001791187-26-000008","document":"form4-09082026_040905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000179118726000008/form4-09082026_040905.xml","form_type":"4"}},{"id":740840,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Option (Right to Buy)","published_at":"2026-06-12T16:30:38.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares earned under a performance-based stock option award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based conditions of the option award, the option was not reportable under Section 16 until the performance conditions were certified by the Issuer's Board of Directors, which occurred on June 11, 2026. The option reported on this form represents 50% of the total number of shares underlying the performance option subject to the option award. The remaining 50% of the shares will be earned upon the satisfaction of additional performance criteria."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option are fully vested and immediately exercisable as of June 1, 2026."}],"balance_after":7500,"derivative":{"exercise_price":16.8,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001791187-26-000006","document":"form4-06122026_040619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000179118726000006/form4-06122026_040619.xml","form_type":"4"}},{"id":859970,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-05T17:43:30.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":24250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":24250,"derivative":{"exercise_price":27.41,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":24250},"source":{"system":"sec-edgar","filing":"0001791187-26-000005","document":"form4-03052026_100327.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000179118726000005/form4-03052026_100327.xml","form_type":"4"}},{"id":859969,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T17:43:30.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":26500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":58544,"source":{"system":"sec-edgar","filing":"0001791187-26-000005","document":"form4-03052026_100327.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000179118726000005/form4-03052026_100327.xml","form_type":"4"}},{"id":910832,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-11T17:32:12.000Z","date":"2026-02-10","kind":"purchase","planned":false,"acquired":true,"shares":6000,"price":21.61,"value":129660.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.24 to $21.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":32044,"source":{"system":"sec-edgar","filing":"0001791187-26-000003","document":"form4-02112026_100208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000179118726000003/form4-02112026_100208.xml","form_type":"4"}},{"id":913273,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-10T16:04:52.000Z","date":"2026-02-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":2077,"price":23.22,"value":48227.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on February 4, 2025."}],"balance_after":26044,"source":{"system":"sec-edgar","filing":"0001791187-26-000002","document":"form4-02102026_090247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000179118726000002/form4-02102026_090247.xml","form_type":"4"}},{"id":1031485,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-09-29T17:00:08.000Z","date":"2025-09-25","kind":"grant","planned":false,"acquired":true,"shares":9860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":9860,"derivative":{"exercise_price":14.71,"expiration_date":"2035-09-24","underlying":"Common Stock","underlying_shares":9860},"source":{"system":"sec-edgar","filing":"0001791187-25-000003","document":"form4-09292025_050905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000179118725000003/form4-09292025_050905.xml","form_type":"4"}},{"id":1031484,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-29T17:00:08.000Z","date":"2025-09-25","kind":"grant","planned":false,"acquired":true,"shares":5430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of September 25, 2026, September 25, 2027 and September 25, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Please note that the total number of securities beneficially owned following the reported transaction has been corrected to reflect the correct amount. The amount reported on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on February 7, 2025 should have reflected that the total number of securities beneficially owned following the reported transaction was 22,691 shares instead of 4,617 shares."}],"balance_after":28121,"source":{"system":"sec-edgar","filing":"0001791187-25-000003","document":"form4-09292025_050905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000179118725000003/form4-09292025_050905.xml","form_type":"4"}},{"id":1279524,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-07T16:19:30.000Z","date":"2025-02-05","kind":"purchase","planned":false,"acquired":true,"shares":4617,"price":54.14,"value":249964.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended."},{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended."}],"balance_after":4617,"source":{"system":"sec-edgar","filing":"0001415889-25-003350","document":"form4-02072025_090225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000141588925003350/form4-02072025_090225.xml","form_type":"4"}},{"id":1280917,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-06T16:05:12.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":32862,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in 48 equal monthly installments beginning on March 4, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":32862,"derivative":{"exercise_price":48.01,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":32862},"source":{"system":"sec-edgar","filing":"0001415889-25-003227","document":"form4-02062025_040206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000141588925003227/form4-02062025_040206.xml","form_type":"4"}},{"id":1280916,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-06T16:05:12.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":18074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of February 4, 2026, February 4, 2027 and February 4, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":18074,"source":{"system":"sec-edgar","filing":"0001415889-25-003227","document":"form4-02062025_040206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000141588925003227/form4-02062025_040206.xml","form_type":"4"}},{"id":1471419,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-06-24T16:18:22.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":118000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as to 25% of the shares on June 20, 2025 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date and to certain change of control acceleration provisions."}],"balance_after":118000,"derivative":{"exercise_price":16.8,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":118000},"source":{"system":"sec-edgar","filing":"0001415889-24-017958","document":"form4-06242024_080618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000141588924017958/form4-06242024_080618.xml","form_type":"4"}},{"id":2070948,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T17:04:16.000Z","date":"2023-01-03","kind":"disposition_to_issuer","acquired":false,"shares":87900,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2032-01-09","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001209191-23-001073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919123001073/doc4.xml","form_type":"4"}},{"id":2070947,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T17:04:16.000Z","date":"2023-01-03","kind":"disposition_to_issuer","acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":13.78,"expiration_date":"2031-08-26","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-23-001073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919123001073/doc4.xml","form_type":"4"}},{"id":2070946,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T17:04:16.000Z","date":"2023-01-03","kind":"disposition_to_issuer","acquired":false,"shares":50500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":18.77,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":50500},"source":{"system":"sec-edgar","filing":"0001209191-23-001073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919123001073/doc4.xml","form_type":"4"}},{"id":2070945,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T17:04:16.000Z","date":"2023-01-03","kind":"disposition_to_issuer","acquired":false,"shares":72648,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":32.65,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":72648},"source":{"system":"sec-edgar","filing":"0001209191-23-001073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919123001073/doc4.xml","form_type":"4"}},{"id":2070944,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T17:04:16.000Z","date":"2023-01-03","kind":"disposition_to_issuer","acquired":false,"shares":161251,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":11.51,"expiration_date":"2029-07-25","underlying":"Common Stock","underlying_shares":161251},"source":{"system":"sec-edgar","filing":"0001209191-23-001073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919123001073/doc4.xml","form_type":"4"}},{"id":2070943,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2023-01-04T17:04:16.000Z","date":"2023-01-03","kind":"disposition_to_issuer","acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"This line item represents performance stock units (\"PSUs\") held by the Reporting Person. Each PSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested PSU was converted into a time-based vesting restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the target number of shares deliverable under such PSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such PSUs immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested PSU was converted into a time-based vesting restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the target number of shares deliverable under such PSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such PSUs immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"expiration_date":"2032-07-05","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-23-001073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919123001073/doc4.xml","form_type":"4"}},{"id":2070942,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-04T17:04:16.000Z","date":"2023-01-03","kind":"disposition_to_issuer","acquired":false,"shares":20236,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This line item represents unvested restricted stock units with respect to the Issuer's common stock (\"RSUs\") held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested RSU or portion thereof was converted into a restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the total number of shares deliverable under such RSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such RSUs immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This line item represents unvested restricted stock units with respect to the Issuer's common stock (\"RSUs\") held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested RSU or portion thereof was converted into a restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the total number of shares deliverable under such RSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such RSUs immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-001073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919123001073/doc4.xml","form_type":"4"}},{"id":2070941,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-04T17:04:16.000Z","date":"2023-01-03","kind":"other","acquired":false,"shares":56289,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. (\"Purchaser\"), a wholly owned subsidiary of Viatris, Inc. (\"Viatris\"), and Viatris, Purchaser commenced a tender offer (the \"Offer\") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer was consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the \"Merger\"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the \"Effective Time\")(continued in Footnote 4)"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the \"Cash Amount\") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the \"Milestone Payment\" and together with the Cash Amount, the \"Per Share Price\") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent."}],"balance_after":20236,"source":{"system":"sec-edgar","filing":"0001209191-23-001073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919123001073/doc4.xml","form_type":"4"}},{"id":2070940,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-04T17:04:16.000Z","date":"2022-01-29","kind":"tax_withholding","acquired":false,"shares":938,"price":11.7,"value":10974.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the Issuer on January 29, 2022 to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units. This transaction is being reported late due to an inadvertent administrative error."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":76525,"source":{"system":"sec-edgar","filing":"0001209191-23-001073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919123001073/doc4.xml","form_type":"4"}},{"id":2095117,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-06T08:50:50.000Z","date":"2022-12-01","kind":"tax_withholding","acquired":false,"shares":3258,"price":11.2,"value":36489.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units (the \"RSUs\"). Such RSUs were previously reported on the Reporting Person's Form 4 as to (i) 11,222 filed with the Securities and Exchange Commission on February 2, 2021 (the \"2021 Award\"); and (ii) 19,500 filed with the Securities and Exchange Commission on January 11, 2022 (the \"2022 Award\"). 2,805 RSUs of the 2021 Award and 4,875 RSUs of the 2022 Award were subsequently accelerated, effective December 1, 2022, resulting in the withholding being reported herein."}],"balance_after":74463,"source":{"system":"sec-edgar","filing":"0001209191-22-059938","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919122059938/doc4.xml","form_type":"4"}},{"id":2210345,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2022-07-08T16:55:28.000Z","date":"2022-07-06","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents a grant of performance stock units (the \"PSUs\"). Each PSU represents a contingent right to receive one share of Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The PSUs will vest as to (i) 50% on July 6, 2023; and (ii) 50% at such time, if any, beginning on July 6, 2023 and ending on July 6, 2024, the 30 day volume-weighted average stock price reaches $6.00 per share (the \"VWAP Vesting Period\"), subject to the Reporting Person's continuous service to the Issuer through each such date. For clarity, the applicable thirty (30) consecutive day period must occur entirely during the VWAP Vesting Period and the thirty (30) day volume-weighted average stock price will be measured during any thirty (30) consecutive trading days during such VWAP Vesting Period."}],"balance_after":300000,"derivative":{"expiration_date":"2032-07-05","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-22-041676","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919122041676/doc4.xml","form_type":"4"}},{"id":2438339,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-01-11T19:45:42.000Z","date":"2022-01-09","kind":"grant","acquired":false,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options granted on January 9, 2022 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. 25% of the options shall vest and become exercisable on January 7, 2023 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date."}],"balance_after":87900,"derivative":{"exercise_price":16,"expiration_date":"2032-01-08","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001209191-22-002978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919122002978/doc4.xml","form_type":"4"}},{"id":2438338,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-11T19:45:42.000Z","date":"2022-01-09","kind":"grant","acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"25% of the RSUs vest on January 7, 2023 and the remainder vest annually thereafter, in equal amounts, on the same day of the month as the grant date over the following 3 years, subject to the Reporting Person's continuous service to the Issuer through each such date."}],"balance_after":77721,"source":{"system":"sec-edgar","filing":"0001209191-22-002978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919122002978/doc4.xml","form_type":"4"}},{"id":2529961,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-11-02T17:49:10.000Z","date":"2021-11-01","kind":"exercise","acquired":false,"shares":8590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the total number of shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances."}],"balance_after":161251,"derivative":{"exercise_price":11.51,"expiration_date":"2029-07-25","underlying":"Common Stock","underlying_shares":8590},"source":{"system":"sec-edgar","filing":"0001209191-21-062476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919121062476/doc4.xml","form_type":"4"}},{"id":2529960,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-02T17:49:10.000Z","date":"2021-11-01","kind":"exercise","acquired":true,"shares":8590,"price":11.51,"value":98870.9,"ownership":{"direct":true},"balance_after":58221,"source":{"system":"sec-edgar","filing":"0001209191-21-062476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919121062476/doc4.xml","form_type":"4"}},{"id":2578002,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-09-07T08:03:56.000Z","date":"2021-09-02","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the total number of shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances."}],"balance_after":169841,"derivative":{"exercise_price":11.51,"expiration_date":"2029-07-25","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-21-054919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919121054919/doc4.xml","form_type":"4"}},{"id":2578001,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-07T08:03:56.000Z","date":"2021-09-02","kind":"exercise","acquired":true,"shares":7500,"price":11.51,"value":86325.0,"ownership":{"direct":true},"balance_after":49631,"source":{"system":"sec-edgar","filing":"0001209191-21-054919","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919121054919/doc4.xml","form_type":"4"}},{"id":2587417,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-08-30T16:52:44.000Z","date":"2021-08-26","kind":"grant","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted on August 26, 2021 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. One-fourth (1/4) of the options shall vest and become exercisable on August 26, 2022 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date."}],"balance_after":45000,"derivative":{"exercise_price":13.78,"expiration_date":"2031-08-26","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-21-053844","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919121053844/doc4.xml","form_type":"4"}},{"id":2622555,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-07-29T17:05:05.000Z","date":"2021-07-28","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the remaining shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances."}],"balance_after":177341,"derivative":{"exercise_price":11.51,"expiration_date":"2029-07-25","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-21-048517","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919121048517/doc4.xml","form_type":"4"}},{"id":2622554,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-07-29T17:05:05.000Z","date":"2021-07-28","kind":"exercise","acquired":true,"shares":7500,"price":11.51,"value":86325.0,"ownership":{"direct":true},"balance_after":42131,"source":{"system":"sec-edgar","filing":"0001209191-21-048517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919121048517/doc4.xml","form_type":"4"}},{"id":2831113,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-02-26T19:50:12.000Z","date":"2021-02-24","kind":"exercise","acquired":false,"shares":9109,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the remaining shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances."}],"balance_after":184841,"derivative":{"exercise_price":11.51,"expiration_date":"2029-07-25","underlying":"Common Stock","underlying_shares":9109},"source":{"system":"sec-edgar","filing":"0001209191-21-015032","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919121015032/doc4.xml","form_type":"4"}},{"id":2831112,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-26T19:50:12.000Z","date":"2021-02-24","kind":"exercise","acquired":true,"shares":9109,"price":11.51,"value":104844.59,"ownership":{"direct":true},"balance_after":34631,"source":{"system":"sec-edgar","filing":"0001209191-21-015032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919121015032/doc4.xml","form_type":"4"}},{"id":2887309,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-02-02T18:32:19.000Z","date":"2021-01-29","kind":"grant","acquired":false,"shares":50500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options granted on January 29, 2021 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. 25% of the options shall vest and become exercisable on January 29, 2022 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date."}],"balance_after":50500,"derivative":{"exercise_price":18.77,"expiration_date":"2031-01-28","underlying":"Common Stock","underlying_shares":50500},"source":{"system":"sec-edgar","filing":"0001209191-21-006929","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919121006929/doc4.xml","form_type":"4"}},{"id":2887308,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-02T18:32:19.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":11222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"25% of the RSUs vest on January 29, 2022 and the remainder vest annually thereafter on the same day of the month as the grant date over the following 3 years, subject to the Reporting Person's continuous service to the Issuer through each such date."}],"balance_after":25522,"source":{"system":"sec-edgar","filing":"0001209191-21-006929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919121006929/doc4.xml","form_type":"4"}},{"id":3022000,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-09-28T18:12:48.000Z","date":"2020-09-25","kind":"exercise","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the remaining shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances."}],"balance_after":193950,"derivative":{"exercise_price":11.51,"expiration_date":"2029-07-25","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001209191-20-052252","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919120052252/doc4.xml","form_type":"4"}},{"id":3021999,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-28T18:12:48.000Z","date":"2020-09-25","kind":"exercise","acquired":true,"shares":4000,"price":11.51,"value":46040.0,"ownership":{"direct":true},"balance_after":14300,"source":{"system":"sec-edgar","filing":"0001209191-20-052252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919120052252/doc4.xml","form_type":"4"}},{"id":3055237,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-18T18:18:58.000Z","date":"2020-08-11","kind":"exercise","acquired":true,"shares":4000,"price":11.51,"value":46040.0,"ownership":{"direct":true},"balance_after":10300,"source":{"system":"sec-edgar","filing":"0001209191-20-047287","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919120047287/doc4a.xml","form_type":"4/A","original_submission_date":"2020-08-12"}},{"id":3061067,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-08-12T20:32:22.000Z","date":"2020-08-11","kind":"exercise","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the remaining shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances."}],"balance_after":197950,"derivative":{"exercise_price":11.51,"expiration_date":"2029-07-25","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001209191-20-046490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919120046490/doc4.xml","form_type":"4"}},{"id":3061066,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-12T20:32:22.000Z","date":"2020-08-11","kind":"exercise","acquired":true,"shares":4000,"price":11.51,"value":46040.0,"ownership":{"direct":true},"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001209191-20-046490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000120919120046490/doc4.xml","form_type":"4"}},{"id":3290081,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-02-05T16:10:22.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":72648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted on February 3, 2019 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan (the \"Plan\"). One quarter of the total number of shares subject to the option shall vest one year after January 1, 2020, and one thirty-sixth of the remaining shares shall continue to vest, monthly thereafter, subject to continued service to the Issuer through each such vesting date."}],"balance_after":72648,"derivative":{"exercise_price":32.65,"expiration_date":"2030-02-02","underlying":"Common Stock, par value $0.001 per share","underlying_shares":72648},"source":{"system":"sec-edgar","filing":"0000899243-20-003254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000089924320003254/doc4.xml","form_type":"4"}},{"id":3381129,"issuer":{"id":15903,"kind":"organization","name":"Oyster Point Pharma, Inc.","symbol":"OYST"},"owners":[{"id":39073,"kind":"person","name":"Lochner Daniel","position":1,"cik":"0001791187","reported_name":"Lochner Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.001 per share","published_at":"2019-11-05T06:08:10.000Z","date":"2019-11-04","kind":"purchase","acquired":true,"shares":6300,"price":16,"value":100800.0,"ownership":{"direct":true},"balance_after":6300,"source":{"system":"sec-edgar","filing":"0000899243-19-026636","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791187/000089924319026636/doc4.xml","form_type":"4"}}]}